AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Data-driven update on AbbVie Inc. intraday activity, highlighting a $2.2B Gubra deal, strategic pipeline moves, and robust dividend signals.
AbbVie targets obesity market, expands RINVOQ in Europe, and navigates inflation. A strategic analysis for investors.
AbbVie (ABBV) navigates biosimilar competition with RINVOQ's potential and a strong dividend, shaping its future growth. Strategic shifts impact investors.
AbbVie navigates Humira biosimilar impact, driving growth through Skyrizi and Rinvoq. Analysis of Q4 2024 results, strategies, and outlook.
AbbVie navigates Humira biosimilar competition, focusing on its immunology and oncology pipelines, strategic collaborations, and dividend growth.
AbbVie navigates Humira's decline with Skyrizi, Rinvoq growth, strategic collaborations, and a focus on shareholder value, positioning it for future success.
AbbVie is driving growth with Skyrizi, Rinvoq, and strategic acquisitions while transitioning beyond Humira to secure long-term value.
AbbVie faces Humira biosimilar challenges, but Skyrizi and Rinvoq drive growth. Leadership transition and strategic acquisitions shape future outlook. All data from Monexa AI.
AbbVie navigates Humira biosimilar impact with strategic diversification, robust pipeline, and commitment to dividends. Skyrizi and Rinvoq drive future growth.
Intraday update on AbbVie Inc.'s strategic shifts beyond Humira with strong dividends, growth drivers, and key acquisitions.
Explore AbbVie's strategic evolution as robust immunology growth offsets Humira's decline and drives future innovation.
A data-driven review of AbbVie’s 2025 strategic shift, leadership transition, pipeline expansion, and market dynamics.